🏅Plantibodies was one of the awarded companies within the 𝙄𝙉𝙉𝙊𝙑𝘼𝙏𝙄𝙊𝙉 𝙁𝙄𝙉𝘼𝙉𝘾𝙄𝘼𝙇 𝙎𝙐𝙋𝙋𝙊𝙍𝙏 category: an innovative biopharming SME from Paris, France developing a drug delivery platform to administer oral biologics targeting the gastrointestinal mucosa, opening up an untapped new frontier in human medicine.

👉 Key Achievements

✅ Successfully Improved the Biopharming Process for Plant-derived Monoclonal Antibodies. The company has shown the ability to produce and bioencapsulate monoclonal antibodies in plant cells, and to release them to the gastrointestinal mucosa. This opens opportunities for further development of Plantibodies delivery platform and is a step forward bringing drug candidates to the clinic, for the patients.

✅ Cost Reduction Potential. Plantibodies has shown its ability to mass produce biotherapies at scale within plants, in a resilient and sustainable way. Moreover, by delivering biologics orally, Plantibodies drastically improves healthcare system resilience. Its drugs are stable at room temperature and can be taken at home by the patients, allowing to avoid burdensome hospital visits while drastically reducing cost for society.

✅ New Cooperation Initiated. The funding facilitated collaborations with European partners, advancing our technology significantly. The unwavering support and dedication from the BioMan4R2 team throughout the program have been particularly noteworthy, enhancing Plantibodies visibility and impact.

🎉Congratulations Plantibodies on your achievements! 🎉